Avanos Medical, Inc. ( (AVNS) ) has released its Q3 earnings. Here is a breakdown of the information Avanos Medical, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avanos Medical, Inc. is a medical technology company focused on providing solutions in the healthcare sector, particularly in specialty nutrition systems and pain management. In its third quarter of 2025, Avanos Medical reported a 4.3% increase in total net sales, reaching $177.8 million, despite a net loss of $1.4 million. The company highlighted double-digit growth in its Specialty Nutrition Systems segment and completed the acquisition of Nexus Medical, which is expected to enhance its offerings in neonatal and pediatric care.
Key financial metrics showed a mixed performance, with adjusted net income decreasing to $10.1 million from $16.7 million the previous year, and adjusted EBITDA dropping to $20.2 million from $30.6 million. The Specialty Nutrition Systems segment saw a significant sales increase, driven by strong demand in enteral feeding and neonate solutions, while the Pain Management & Recovery segment experienced modest growth, with a notable increase in Radio Frequency Ablation product sales.
Despite the challenges, Avanos Medical is optimistic about its future, raising its full-year revenue and adjusted EPS guidance. The company aims to continue its strategic focus on its core segments while navigating the impacts of tariffs and other economic pressures. Avanos Medical’s management remains committed to enhancing its product offerings and operational efficiency to drive future growth.